{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T21:53:35Z","timestamp":1767650015301},"reference-count":27,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2021,5,5]],"date-time":"2021-05-05T00:00:00Z","timestamp":1620172800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008730","name":"Kreftforeningen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008730","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The prevalence of prescribed drugs in survivors of colorectal cancer (CRC) was evaluated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Data from the Cancer Registry of Norway were linked to the Norwegian Prescription Database for a study population of 3.52 million individuals. Prevalence ratios (PRs) with 95% confidence intervals (CIs) of prescribed drugs in CRC\u2010survivors compared to the cancer\u2010free population, were estimated by log\u2010binomial regression, adjusting for age and education.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Almost 27\u2009000 individuals, aged 20 to 84, were diagnosed with CRC during 2005 to 2014. The first year after diagnosis, the prevalence of prescribed drugs was higher in CRC\u2010survivors compared with the cancer\u2010free population, especially drugs for anxiety and tension, and steroid\u2010responsive conditions. PRs for several drugs, especially drugs used for mental and behavioural disorders, decreased with time since diagnosis. The prevalence of drugs used for anxiety and tension was elevated 10\u2009years after diagnosis; PRs the first year after diagnosis were 20 (95% CI: 18\u201022) in males and 17 (16\u201018) in females. Ten years after diagnosis PRs were 5.0 (3.1\u20107.9) and 2.0 (1.0\u20103.8), respectively. In absolute numbers, the largest increase, compared to the cancer\u2010free population, was in drugs used for gastric acid disorders and pain. The prevalence of neuromodulatory drugs was higher in CRC\u2010survivors.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The prevalence of several drugs was higher in CRC\u2010survivors than in the cancer\u2010free population 10\u2009years after diagnosis. The largest absolute excess in prevalence was for gastric acid disorder and pain medications, while the relative prevalence of drugs used for anxiety and tension was high in CRC\u2010survivors. Long persisting neuropathia was indicated.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.5243","type":"journal-article","created":{"date-parts":[[2021,4,6]],"date-time":"2021-04-06T15:25:40Z","timestamp":1617722740000},"page":"1037-1048","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Prescribed drugs in 27\u2009000 individuals after diagnosis of colorectal cancer: A population\u2010based cohort study"],"prefix":"10.1002","volume":"30","author":[{"given":"Anders","family":"Engeland","sequence":"first","affiliation":[{"name":"Department of Chronic Diseases and Ageing Norwegian Institute of Public Health  Oslo Norway"},{"name":"Department of Global Public Health and Primary Care University of Bergen  Bergen Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Ghaderi","sequence":"additional","affiliation":[{"name":"Department of Global Public Health and Primary Care University of Bergen  Bergen Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"dos\u2010Santos\u2010Silva","sequence":"additional","affiliation":[{"name":"Department of Non\u2010communicable Disease Epidemiology London School of Hygiene &amp; Tropical Medicine  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kari","family":"Furu","sequence":"additional","affiliation":[{"name":"Department of Chronic Diseases and Ageing Norwegian Institute of Public Health  Oslo Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vidar","family":"Hjellvik","sequence":"additional","affiliation":[{"name":"Department of Chronic Diseases and Ageing Norwegian Institute of Public Health  Oslo Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rune","family":"Kv\u00e5le","sequence":"additional","affiliation":[{"name":"Department of Chronic Diseases and Ageing Norwegian Institute of Public Health  Oslo Norway"},{"name":"Department of Health Registry Research and Development Norwegian Institute of Public Health  Bergen Norway"},{"name":"Department of Oncology and Medical Physics Haukeland University Hospital  Bergen Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tone","family":"Bj\u00f8rge","sequence":"additional","affiliation":[{"name":"Department of Global Public Health and Primary Care University of Bergen  Bergen Norway"},{"name":"Cancer Registry of Norway  Oslo Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,5,5]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21492"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32319-0"},{"key":"e_1_2_10_4_1","unstructured":"DanckertB FerlayJ EngholmG et al.NORDCAN: Cancer Incidence Mortality Prevalence and Survival in the Nordic Countries Version 8.2 (26.03.2019): Association of the Nordic Cancer Registries. Danish Cancer Society 2019."},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-0950-3"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2013.541"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31674-5"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2009.0058"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2019.01.023"},{"issue":"26","key":"e_1_2_10_10_1","first-page":"2550","article-title":"The central population registry in medical research","volume":"122","author":"Hammer H","year":"2002","journal-title":"Tidsskr Nor Laegeforen"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.037"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-7843.2009.00494.x"},{"key":"e_1_2_10_13_1","volume-title":"The Norwegian Prescription Database 2013\u20132017","author":"Berg C","year":"2018"},{"key":"e_1_2_10_14_1","unstructured":"Statistics Norway.Statistics Norway;2021updated 2016. Available from: ssb.no accessed January 30 2021."},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0000000000000149"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21286"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61899-6"},{"key":"e_1_2_10_18_1","volume-title":"Age Standardization of Rates: A New WHO Standard. GPE Discussion Paper Series: No 31","author":"Ahmad OB","year":"2001"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70244-4"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.7192"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000001459"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djz040"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-6109.2012.02894.x"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.4251\/wjgo.v8.i3.258"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00086"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-014-2242-z"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9082400"},{"key":"e_1_2_10_28_1","volume-title":"Legemiddelstatistikk","author":"Sakshaug S","year":"2017"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.5243","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/pds.5243","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.5243","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T04:19:10Z","timestamp":1692850750000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.5243"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,5]]},"references-count":27,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["10.1002\/pds.5243"],"URL":"https:\/\/doi.org\/10.1002\/pds.5243","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,5]]},"assertion":[{"value":"2020-11-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-30","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-05","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}